Vidarabine therapy for severe herpesvirus infections. An unusual syndrome of chronic varicella and transient immunologic deficiency.
Six patients with severe herpesvirus infections were successfully treated with vidarabine. One patient had a previously undescribed syndrome of chronic cutaneous varicella infection of eight months' duration, associated with transient but complete duppression of lymphocyte response to conconavalin A. Other diagnoses were severe varicella pneumonia, progressive cytomegalovirus pneumonia associated with acute lymphocytic leukemia, herpes simplex encephalitis, severe zoster associated with stage IV lymphoma, and disseminated herpes simplex in a patient receiving high doses of steroids. All patients showed cessation of new lesions or abrupt clinical improvement between days 2 and 4 after initiation of therapy, and all were cured of their clinical infection. Dramatic improvement in all of our patients and the minimal toxicity observed make vidarabine suitable for use in severe herpesvirus infections.
D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000188:drug therapy*; D002908:Chronic Disease; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004660:Encephalitis / Q000188:drug therapy; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy; D006562:Herpes Zoster / Q000188:drug therapy; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011024:Pneumonia, Viral / Q000188:drug therapy; D011684:Purine Nucleosides / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013577:Syndrome; D014740:Vidarabine / Q000627:therapeutic use*
D011684:Purine Nucleosides; D014740:Vidarabine